课题基金 / 基金详情

项目摘要

项目成果

Manfred Brigl的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):自然杀伤T(NKT)细胞是一种进化上保守的先天性T细胞亚群,可识别由CD 1d分子呈递的脂质抗原。NKT细胞已被证明在自身免疫以及对癌症和感染的免疫中起关键作用。除了广泛研究的利用V <$14-J <$18 TCR <$链并识别原型<$-半乳糖神经酰胺抗原的不变NKT(iNKT)细胞外,还存在利用不同TCR的CD 1d限制性NKT细胞(dNKT或II型NKT细胞)。现有数据表明,dNKT细胞具有与iNKT细胞不同的抗原特异性和功能能力。然而,目前尚不清楚dNKT细胞是否识别微生物脂质抗原,它们是否具有产生记忆反应的能力,以及它们在感染期间的功能是什么。理解这些关键问题的进展在很大程度上阻碍了B缺乏特异性识别和研究dNKT细胞的标记物,抗原和工具。我们的长期目标是了解dNKT细胞的抗原特异性,它们对微生物刺激的反应功能,以及它们在结核分枝杆菌感染过程中的作用。这里的目标,这是追求这一目标的下一步,是生成和表征用于体内研究dNKT细胞的TCR-逆转录小鼠模型。基于先前未被认识到的能力,dNKT细胞识别不同的分枝杆菌脂质抗原,并被Mtb感染的APC刺激,我们的中心假设是,dNKT细胞在Mtb感染过程中具有保护功能。我们的策略是产生和表征表达由Mtb特异性dNKT细胞使用的TCR的逆转录(Rg)小鼠。Rg小鼠的产生是一种使用逆转录病毒和干细胞介导的基因转移快速表达确定的TCR和TCR蛋白的新方法。我们已经使用该方法成功地产生了四个Rg小鼠系,其表达来自Mtb特异性CD 8 + T细胞的MHC I类限制性TCR。我们计划测试我们的中心假设,从而通过产生和表征表达CD 1d限制性Mtb特异性dNKT细胞TCR的TCR逆转录小鼠来实现本申请的目的(目的1)。然后,我们将在体外和体内表征抗原刺激和Mtb感染后这些转基因小鼠中的Mtb特异性dNKT细胞应答(目的2)。关于预期的结果,拟议的研究将产生一个鼠体内系统,使研究的dNKT细胞功能的Mtb抗原的反应和Mtb感染。这些研究预计将产生重大影响,因为它们将开发出第一个用于体内研究dNKT细胞的易处理的小动物模型,该模型可用于研究dNKT细胞对各种疾病过程的贡献。第二,我们希望确定dNKT细胞在分枝杆菌感染过程中的作用,这可能会导致识别新的抗原靶点,这些靶点可以被纳入抗结核分枝杆菌的疫苗中。这项工作将从根本上推进CD 1d/dNKT细胞生物学领域。
英文摘要
DESCRIPTION (provided by applicant): Natural Killer T (NKT) cells are an evolutionarily conserved subset of innate-like T cells that recognizes lipid antigens presented by CD1d molecules. NKT cells have been shown to play critical roles in autoimmunity, and in immunity to cancer and infection. In addition to the widely studied invariant NKT (iNKT) cells that utilize V¿14-J¿18 TCR¿-chains and recognize the prototypical ¿-galactosylceramide antigen, CD1d-restricted NKT cells utilizing diverse TCRs (dNKT or type II NKT cells) exist. Available data suggest that dNKT cells have antigen specificities and functional capabilities that are distinct from those of iNKT cells. However, it is not known whether dNKT cells recognize microbial lipid antigens, whether they have the ability to generate memory responses, and what their function is during infection. Progress in understanding these critical questions is in large part hindered b the lack of markers, antigens, and tools to specifically identify and study dNKT cells. Our long-term goal is to understand the antigen specificity of dNKT cells, their function in response to microbial stimulation, and their role during Mtb infection. The objective here, which is the next step in pursuit of that goal, is to generate and characterize a TCR-retrogenic mouse model for the in vivo study of dNKT cells. Based on the previously unrecognized ability of dNKT cells to recognize diverse mycobacterial lipid antigens and to be stimulated by Mtb-infected APCs, our central hypothesis is that dNKT cells have a protective function during Mtb infection. Our strategy is to generate and characterize retrogenic (Rg) mice expressing the TCRs used by Mtb-specific dNKT cells. Generation of Rg mice is a novel method for rapid expression of defined TCR¿ and ¿ proteins that uses retroviral and stem cell-mediated gene transfer. We have used this method successfully to generate four Rg mouse lines that express MHC class I- restricted TCRs from Mtb-specific CD8+ T cells. We plan to test our central hypothesis and, thereby, accomplish the objective of this application by generating and characterizing TCR-retrogenic mice expressing CD1d-restricted Mtb-specific dNKT cell TCRs (Aim 1). We will then characterize Mtb-specific dNKT cell responses in those retrogenic mice following antigen stimulation and Mtb infection in vitro and in vivo (Aim 2). With respect to expected outcomes, the proposed studies will generate a murine in vivo system to enable studies of dNKT cell function in response to Mtb antigens and during Mtb infection. These studies are expected to have a significant impact because they will develop the first tractable small animal model for the study of dNKT cells in vivo, a model that can be used to study the contribution of dNKT cells to a variety of disease processes. Second, we expect to define the role of dNKT cells during mycobacterial infection, which may result in the identification of new antigen targets that could be incorporated into vaccines against Mtb. This work will fundamentally advance the field of CD1d/dNKT cell biology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MR1 and MAIT Cell Function in Intestinal Infection
  • 批准号:
    9302658
  • 项目类别:
  • 资助金额:
    $62.17万
  • 财政年份:
    2016
  • 负责人:
    Manfred Brigl
  • 依托单位:
Role of type II NKT cells during M. tuberculosis infection
  • 批准号:
    8582986
  • 项目类别:
  • 资助金额:
    $21.54万
  • 财政年份:
    2013
  • 负责人:
    Manfred Brigl
  • 依托单位:
CD1d-restricted NKT cells in microbial infection
  • 批准号:
    8112316
  • 项目类别:
  • 资助金额:
    $5.0万
  • 财政年份:
    2010
  • 负责人:
    Manfred Brigl
  • 依托单位:
CD1d-restricted NKT cells in microbial infection
  • 批准号:
    7920657
  • 项目类别:
  • 资助金额:
    $5.0万
  • 财政年份:
    2009
  • 负责人:
    Manfred Brigl
  • 依托单位:
海外基金